{"pmid":32476258,"title":"Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States.","text":["Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States.","The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among ten SOT patients, including the clinical presentation, treatment modalities, and outcomes of seven renal transplant recipients, one liver transplant recipient, one heart transplant recipient, and one lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all seven hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community.","Am J Transplant","Fung, Monica","Chiu, Charles Y","DeVoe, Catherine","Doernberg, Sarah B","Schwartz, Brian S","Langelier, Charles","Henrich, Timothy J","Yokoe, Deborah","Davis, John","Hays, Steven R","Chandran, Sindhu","Kukreja, Jasleen","Ng, Dianna","Prostko, John","Taylor, Russell","Reyes, Kevin","Bainbridge, Emma","Bond, Allison","Chin-Hong, Peter","Babik, Jennifer M","32476258"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among ten SOT patients, including the clinical presentation, treatment modalities, and outcomes of seven renal transplant recipients, one liver transplant recipient, one heart transplant recipient, and one lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all seven hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community."],"journal":"Am J Transplant","authors":["Fung, Monica","Chiu, Charles Y","DeVoe, Catherine","Doernberg, Sarah B","Schwartz, Brian S","Langelier, Charles","Henrich, Timothy J","Yokoe, Deborah","Davis, John","Hays, Steven R","Chandran, Sindhu","Kukreja, Jasleen","Ng, Dianna","Prostko, John","Taylor, Russell","Reyes, Kevin","Bainbridge, Emma","Bond, Allison","Chin-Hong, Peter","Babik, Jennifer M"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476258","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16079","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1668437834963353600,"score":9.490897,"similar":[{"pmid":32460390,"title":"Covid-19 in solid organ transplant recipients: A single center experience.","text":["Covid-19 in solid organ transplant recipients: A single center experience.","BACKGROUND: Solid organ transplant (SOT) recipients may be at risk for severe COVID-19. Data on the clinical course of COVID-19 in immunosuppressed patients are limited and the effective treatment strategy for these patients is unknown. METHODS: We describe our institutional experience with COVID-19 in SOT. Demographic, clinical and treatment data were extracted from the electronic patient files. RESULTS: A total of 23 SOT transplant recipients suffering from COVID-19 were identified (n = 3 heart; n =15 kidney; n = 1 kidney-after-heart; n = 3 lung and n = 1 liver transplant recipient). The presenting symptoms were similar to non-immunocompromised patients Eighty-three percent (19/23) of the patients required hospitalization but only two of these were transferred to the intensive care unit. Five patients died from COVID-19; all had high Clinical Frailty scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only 3 patients were treated with chloroquine. Most patients recovered without experimental anti-viral therapy. CONCLUSIONS: Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID-19. Pre-existent frailty is associated with death from COVID-19.","Transpl Int","Hoek, Rogier A S","Manintveld, Olivier C","Betjes, Michiel G H","Hellemons, Merel E","Seghers, Leonard","van Kampen, Jeroen A A","Caliskan, Kadir","van de Wetering, Jacqueline","van den Hoogen, Martijn","Metselaar, Herold J","Hesselink, Dennis A","32460390"],"abstract":["BACKGROUND: Solid organ transplant (SOT) recipients may be at risk for severe COVID-19. Data on the clinical course of COVID-19 in immunosuppressed patients are limited and the effective treatment strategy for these patients is unknown. METHODS: We describe our institutional experience with COVID-19 in SOT. Demographic, clinical and treatment data were extracted from the electronic patient files. RESULTS: A total of 23 SOT transplant recipients suffering from COVID-19 were identified (n = 3 heart; n =15 kidney; n = 1 kidney-after-heart; n = 3 lung and n = 1 liver transplant recipient). The presenting symptoms were similar to non-immunocompromised patients Eighty-three percent (19/23) of the patients required hospitalization but only two of these were transferred to the intensive care unit. Five patients died from COVID-19; all had high Clinical Frailty scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only 3 patients were treated with chloroquine. Most patients recovered without experimental anti-viral therapy. CONCLUSIONS: Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID-19. Pre-existent frailty is associated with death from COVID-19."],"journal":"Transpl Int","authors":["Hoek, Rogier A S","Manintveld, Olivier C","Betjes, Michiel G H","Hellemons, Merel E","Seghers, Leonard","van Kampen, Jeroen A A","Caliskan, Kadir","van de Wetering, Jacqueline","van den Hoogen, Martijn","Metselaar, Herold J","Hesselink, Dennis A"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460390","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/tri.13662","keywords":["covid-19","sars-cov-2","organ transplantation","solid organ transplantation"],"topics":["Treatment"],"weight":1,"_version_":1667967698947014659,"score":572.81165},{"pmid":32315122,"title":"COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient.","text":["COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly infecting people worldwide, resulting in the infectious disease coronavirus disease 19 (COVID-19) that has been declared a pandemic. Much remains unknown about COVID-19, including its effects on solid organ transplant (SOT) recipients. Given their immunosuppressed state, SOT recipients are presumed to be at high risk of complications with viral infections such as SARS-CoV-2. Limited case reports in single SOT recipients, however, have not suggested a particularly severe course in this population. In this report, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and, despite the presence of a number of risk factors for poor outcomes, had a relatively mild clinical course.","Am J Transplant","Hsu, Jeffrey J","Gaynor, Pryce","Kamath, Megan","Fan, Ashley","Al-Saffar, Farah","Cruz, Daniel","Nsair, Ali","32315122"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly infecting people worldwide, resulting in the infectious disease coronavirus disease 19 (COVID-19) that has been declared a pandemic. Much remains unknown about COVID-19, including its effects on solid organ transplant (SOT) recipients. Given their immunosuppressed state, SOT recipients are presumed to be at high risk of complications with viral infections such as SARS-CoV-2. Limited case reports in single SOT recipients, however, have not suggested a particularly severe course in this population. In this report, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and, despite the presence of a number of risk factors for poor outcomes, had a relatively mild clinical course."],"journal":"Am J Transplant","authors":["Hsu, Jeffrey J","Gaynor, Pryce","Kamath, Megan","Fan, Ashley","Al-Saffar, Farah","Cruz, Daniel","Nsair, Ali"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315122","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15936","topics":["Case Report"],"weight":1,"_version_":1666138493435248640,"score":564.7072},{"pmid":32412159,"title":"First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.","text":["First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.","Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%) and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts.","Am J Transplant","Tschopp, J","L'Huillier, A G","Mombelli, M","Mueller, N J","Khanna, N","Garzoni, C","Meloni, D","Papadimitriou-Olivgeris, M","Neofytos, D","Hirsch, H H","Schuurmans, M M","Muller, T","Berney, T","Steiger, J","Pascual, M","Manuel, O","van Delden, C","32412159"],"abstract":["Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%) and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts."],"journal":"Am J Transplant","authors":["Tschopp, J","L'Huillier, A G","Mombelli, M","Mueller, N J","Khanna, N","Garzoni, C","Meloni, D","Papadimitriou-Olivgeris, M","Neofytos, D","Hirsch, H H","Schuurmans, M M","Muller, T","Berney, T","Steiger, J","Pascual, M","Manuel, O","van Delden, C"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412159","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.16062","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666897319106183168,"score":515.6606},{"pmid":32282986,"title":"Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients.","text":["Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients.","Over 1 000 000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants. We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses. The first patient received liver transplantation due to hepatitis B virus-related hepatocellular carcinoma and was confirmed to have COVID-19 9 days later. Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered. The other patient had undergone a renal transplant from a living-related donor 17 years ago, and was admitted to the hospital because of persistent fever. This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use. No signs of rejection were observed during the regimen. In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients.","Am J Transplant","Zhong, Zibiao","Zhang, Qiuyan","Xia, Haoyang","Wang, Aiping","Liang, Wenjin","Zhou, Wei","Zhou, Lihua","Liu, Xiao","Rao, Lingzhang","Li, Zhifeng","Peng, Zhiyong","Mo, Pingzheng","Xiong, Yong","Ye, Shaojun","Wang, Yanfeng","Ye, Qifa","32282986"],"abstract":["Over 1 000 000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants. We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses. The first patient received liver transplantation due to hepatitis B virus-related hepatocellular carcinoma and was confirmed to have COVID-19 9 days later. Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered. The other patient had undergone a renal transplant from a living-related donor 17 years ago, and was admitted to the hospital because of persistent fever. This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use. No signs of rejection were observed during the regimen. In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients."],"journal":"Am J Transplant","authors":["Zhong, Zibiao","Zhang, Qiuyan","Xia, Haoyang","Wang, Aiping","Liang, Wenjin","Zhou, Wei","Zhou, Lihua","Liu, Xiao","Rao, Lingzhang","Li, Zhifeng","Peng, Zhiyong","Mo, Pingzheng","Xiong, Yong","Ye, Shaojun","Wang, Yanfeng","Ye, Qifa"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282986","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15928","keywords":["covid-19","clinical characteristics","immunosuppressant","solid organ transplant recipient"],"e_drugs":["Methylprednisolone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138491464974336,"score":509.63766},{"pmid":32301155,"title":"COVID-19 in solid organ transplant recipients: a single-center case series from Spain.","text":["COVID-19 in solid organ transplant recipients: a single-center case series from Spain.","The clinical characteristics, management and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplantation (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 +/- 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine [HCQ]) was used in 50.0% of patients, and had to be prematurely discontinued in two of them. Other antiviral regimens included HCQ monotherapy (27.8%) and interferon-beta (16.7%). As of April 4, the case fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C reactive protein levels at various points were significantly higher among recipients that experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.","Am J Transplant","Fernandez-Ruiz, Mario","Andres, Amado","Loinaz, Carmelo","Delgado, Juan F","Lopez-Medrano, Francisco","San Juan, Rafael","Gonzalez, Esther","Polanco, Natalia","Folgueira, Maria Dolores","Lalueza, Antonio","Lumbreras, Carlos","Aguado, Jose Maria","32301155"],"abstract":["The clinical characteristics, management and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplantation (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 +/- 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine [HCQ]) was used in 50.0% of patients, and had to be prematurely discontinued in two of them. Other antiviral regimens included HCQ monotherapy (27.8%) and interferon-beta (16.7%). As of April 4, the case fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C reactive protein levels at various points were significantly higher among recipients that experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients."],"journal":"Am J Transplant","authors":["Fernandez-Ruiz, Mario","Andres, Amado","Loinaz, Carmelo","Delgado, Juan F","Lopez-Medrano, Francisco","San Juan, Rafael","Gonzalez, Esther","Polanco, Natalia","Folgueira, Maria Dolores","Lalueza, Antonio","Lumbreras, Carlos","Aguado, Jose Maria"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301155","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15929","keywords":["covid-19","sars-cov-2","coronavirus","outcome","solid organ transplantation","treatment"],"locations":["Madrid","Spain"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"e_drugs":["Hydroxychloroquine","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1666138494803640321,"score":509.5886}]}